Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Lars Buschhorn(National Center for Tumor Diseases), Diego de Miguel‐Pérez(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Marzia Del Re(University of Pisa), Filip Jankú(The University of Texas MD Anderson Cancer Center), Christian Rolfo(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Adam Wahida(National Center for Tumor Diseases), Andreas Schneeweiß(Heidelberg University), Giuseppe Curigliano(European Institute of Oncology), Nagla Abdel Karim(Augusta University), Alessandro Russo(University of Messina)
Cited by 103
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k